Close
CDMO Safety Testing 2026
Novotech

Overcoming challenges in effervescent dosage manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire...

Are Glutathione Injections in NYC Worth It? A Complete Guide

When whatever you do to your skin makes it...
- Advertisement -

To improve the taste and stability of effervescent tablets and powders, BENEO presents galenIQ™ 721. This filler-binder enables pharmaceutical and nutraceutical manufacturers to target consumers that have difficulty swallowing standard tablets. As a non-hygroscopic, water-soluble and directly compressible excipient, galenIQ™ 721 also provides high content uniformity and production efficiency for effervescent applications.

Effervescent dosage forms offer distinct advantages compared with traditional tablets. For instance, many patients have problems swallowing tablets. Effervescent powders and tablets offer a more convenient way to deliver medicines or dietary supplements. They dissolve upon contact with water to release carbon dioxide and create a drink. In addition, they can be used to formulate pharmaceuticals that are difficult to digest, that cause stomach or esophageal irritation or that rely on a rapid onset of action, such as analgesics.

However, manufacturing effervescent dosage forms is often challenging. To produce highly stable tablets, a non-hygroscopic, direct compression filler-binder such as galenIQ™ 721 is needed. It ensures high content uniformity and facilitates production. BENEO’s excipient has a sugar-like taste profile, a pleasant mouthfeel and can enhance the palatability of effervescent formulations. Furthermore it is non-cariogenic and therefore is both sweet and tooth-friendly.

Dr Maj-Britt Cepok, Head of Business Development, Pharma, BENEO, comments: “Fizzy tablets are ideally suited to administer a wide range of light-, oxygen- and other sensitive active ingredients and those that require a large dose. In addition, effervescent preparations are more appealing to consumers than traditional dosage forms. galenIQ™ 721 helps manufacturers to tap into this market and enhance their development programs.”

About galenIQ™
BENEO is part of the Südzucker Group and a member of the International Pharmaceutical Excipients Council (IPEC). The company produces galenIQ™ (Isomalt Ph. Eur., BP, USP-NF, JP), a multifunctional range of water-soluble filler-binders according to cGMP conditions for pharmaceutical excipients. galenIQ™ is available in a wide variety of median particle sizes, morphologies and solubilities and therefore is readily used in solid and liquid dosage forms such as tablets, sachets, effervescents, lozenges and syrups. It is physically and chemically stable, non-hygroscopic and enhances the palatability of the final form.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire...

Are Glutathione Injections in NYC Worth It? A Complete Guide

When whatever you do to your skin makes it...

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »